Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe
File(s)
Author(s)
Type
Journal Article
Abstract
Hepatitis C virus (HCV) infection is a systemic disease associated with both hepatic and extrahepatic manifestations. The burden associated with the hepatic manifestation of HCV infection has been well documented in Europe, although that of HCV extrahepatic manifestations remains unknown. In this study, we estimated the annual direct medical costs associated with HCV extrahepatic manifestations in five European countries. A previously validated economic model was used to estimate the annual direct medical cost associated with HCV extrahepatic manifestations. Global excess prevalence of extrahepatic manifestations in HCV patients relative to that in non-HCV patients was obtained from a recent meta-analysis. Per-patient per-year inpatient, outpatient and medication costs to treat each extrahepatic manifestation were from the literature, national databases or expert opinion if unavailable otherwise. All costs were adjusted to 2016 euros (€). The overall direct medical costs associated with HCV extrahepatic manifestations were calculated by multiplying the total per-patient per-year costs of each by the respective excess prevalence rates and then by the size of the HCV-infected population in each country. Treatment impact with direct-acting antivirals (DAAs) was explored using HCV extrahepatic manifestations excess prevalence rates among cured patients compared to untreated HCV patients, as sourced from a meta-analysis. The total annual direct medical cost associated with HCV extrahepatic manifestations was estimated to be 2.17 billion euro (€), with a per-HCV-patient cost ranging from €899 to €1647 annually. DAA treatment was projected to result in cost savings of €316 million per year. We find that the annual economic burden of extrahepatic manifestations is significant and may be partly mitigated by treatment with DAAs.
Date Issued
2018-07-01
Date Acceptance
2018-01-16
Citation
Journal of Viral Hepatitis, 2018, 25 (7), pp.811-817
ISSN
1352-0504
Publisher
Wiley
Start Page
811
End Page
817
Journal / Book Title
Journal of Viral Hepatitis
Volume
25
Issue
7
Copyright Statement
© 2018 John Wiley & Sons Ltd. This is the pre-peer reviewed version of the following article, which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.12881
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/29476572
Subjects
Europe
burden of disease
burden of illness
direct-acting antivirals
extrahepatic manifestations
hepatitis C
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2018-02-24